Correction for Chan et al., “A Novel, Multiple-Antigen Pneumococcal Vaccine Protects against Lethal Streptococcus pneumoniae Challenge”

Volume 87, no. 3, e00846-18, 2019, https://doi.org/10.1128/IAI.00846-18. Corrections in the Abstract, Materials and Methods, Results, and Discussion were made to the article since an error in labeling one of the batches of the multiple-antigen vaccine (MAV) preparations (specifically, the culture conditions for MAV batch IPS004 [MAVIPS004] and MAVIPS005) caused confusion about interpretation of the results. MAVIPS004 and MAVIPS005 were cultured at 30°C, with the MAVIPS004 also having a short period at 37°C before processing further. Hence, comparison of these products does not properly assess the effects of heat shock on antigenicity. The comparison of these two products remains an important part of the development of the production process for vaccine clinical material, with the comparison of the antigen content between MAVIPS004 and MAVIPS005 needed to show that reducing the culture temperature to 30°C did not affect the antigenicity of the MAV product. A revised version of the manuscript that corrects these errors is being published simultaneously (https://doi.org/10.1128/iai.00846-18a).